Alireza A. Shamshirsaz
Department Director, Professor of Surgery
Maternal Fetal Care Center (MFCC), Boston Children’s Hospital, Harvard Medical School
BOSTON, Massachusetts, United States
Alireza A. Shamshirsaz, MD, FACOG, currently serves as the Director of the Maternal Fetal Care Center (MFCC), Director of Perinatl Surgery Fellowship and Director of Maternal Fetal Medicine at Boston Children’s Hospital. He has held the position of Professor of Surgery at Harvard Medical School since 2022. Dr. Shamshirsaz is a Fetal Surgeon and is dual board-certified in obstetrics and gynecology as well as maternal fetal medicine. He also holds the positions of Vice Chair of the SMFM Education Committee, Co-editor in Chief of the Clinical Obstetrics and Gynecology Journal, and Chair of the Steering Committee of the North American Fetal Therapy Network (NAFTNet).
Over the course of his professional career in the field of maternal fetal medicine spanning two decades, he has published more than 280 peer-reviewed papers. These primarily focus on complex monochorionic pregnancies, lower urinary tract obstruction, neural tube defects, and placenta accreta spectrum disorders. He has also contributed to and led over 40 systematic reviews and meta-analyses in the field. Additionally, he has spearheaded several international qualitative studies aiming to establish clinical guidelines for controversial topics within the field.
In his current role, Dr. Shamshirsaz’s research primarily centers on the following three domains:
1) Innovative Fetal Intervention: Dr. Shamshirsaz and his research team are exploring several innovative surgeries for patients with congenital hydrocephalus and vasa previa (FLUMEN study).
2) Innovative Medical Therapies: He has initiated two projects at his current position: one examining the efficacy of Sirolimus in congenital cervicofacial malformations (MaterPons study) and the other assessing the efficacy of Valacyclovir in treating congenital CMV infections.
3) Mesenchymal Stem Cells: His team is investigating the potential of MSCs in treating fetal anomalies.
